

## Magnophos

### Solution for injection

### Calcium,Magnesium,Phosphate

#### COMPOSITION

One ml contains Active substance(s):

Calcium glucohepto gluconate (equivalent to Calcium 5.7mg)	100.0mg
Magnesium hypophosphite	32.0mg
Excipient(s):	
Methyl parahydroxybenzoate(E218)	0.8mg
Propyl parahydroxybenzoate(E216)	0.2mg
Sodium metabisulphite(E222)	1.0mg
Ascorbic acid	25mg

#### PRESENTATION

Vial of 250ml

#### TARGET SPECIES

Cattle, horses, calves.

Slow I.V, I.M. administration

#### INDICATIONS

In cattle, horses and calves: Prevention and treatment of hypocalcaemia and/or hypomagnesaemia and/or hypophosphataemia such as: milk fever, parturient paresis, grass tetany, eclampsia.

#### POSODOLOGY, METHOD AND ROUTES OF ADMINISTRATION

Administration route: Slow intravenous, intramuscular.

0.12 to 0.24 mg of calcium and 0.64 to 1.28 mg of magnesium hypophosphite per kg live weight per administration, equivalent to 0.2 ml to 0.4 ml per 10 kg live weight per slow intravenous or intramuscular administration, corresponding to:

Cattle, horses:

Adults: 10 to 20 ml intravenous or intramuscular injection per day every 2 to 3 days

Young animals: 5 to 10 ml deep intramuscular injection per day

## CONTRAINDICATIONS

Do not use in animals with heart disorders.

## ADVERS EEEFFECTS

During intramuscular administration, local tissue reactions at the injection site may be observed. Too rapid intravenous administration can cause cardiac arrhythmia and lead to fatal collapse. Symptoms of hypercalcaemia can occur during the 30 minutes after administration (tremors, excitation, sweating, hypotonia and collapse).

## SPECIAL WARNINGS

**Special warnings for each target species : None**

**Special precautions for use in animals :**

The solution must be warmed to body temperature before administration. Intravenous administration must be slow , and stopped immediately if side effects occur.

During intramuscular administration, divide the dose between Several injection sites to limit local reactions.

The use and reuse of this product must undergo benefit/risk evaluation depending on possible previous treatments , in particular calcium based treatments.

**Special precautions to be taken by the person administering the medicinal product to animals**

None.

**Use during pregnancy or lactation**

The safety of the medicinal product has not been evaluated in the target species during pregnancy and lactation. However, the use of the medicinal product during pregnancy and lactation does not pose a particular problem.

## Interactions

None known.

## Overdose

See "Adverse effects" section.

## Incompatibilities

Compatibility with another medicinal product must be checked before mixing to prevent precipitate from forming.

### **STORAGE CONDITIONS**

Shelf-life after first opening :28days.

Do not store above 25°C.

Keep out of the reach and sight of children.

### **WITHDRAWAL PERIOD**

Meat and offal :Zero days.

Milk : Zero hours.

### **SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED VETERINARY MEDICINAL PRODUCTOR WASTE MATERIALS DERIVED FROM THE USE OF SUCH PRODUCTS**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local regulations.

**FOR ANIMAL TREATMENT ONLY**

**TO BE SUPPLIED ONLY ON VETERINARY PRESCRIPTION**